PHC Live Cell Metabolic Analyzer (LiCellMo) Receives 2024 Innovation Award from The Analytical Scientist
Author of the article:
Published on December 12, 2024 • 3 minutes read
Article content
TOKYO – The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura), has received the 2024 Innovation Award from The Analytical Scientist1 cell metabolic analyzer, LiCellMoTM. LiCellMo, launched for research use in Japan in September and the United States, UK, EU, China and other selected Asian territories in October.2provides continuously measured data on important cellular metabolic pathways3giving researchers a more accurate picture of previously unseen changes in the state of cells over time and allowing them to make more informed research decisions. This will help in finding new research and important advances in treatment. It is designed to reveal the metabolic pathways of cells and improve the reproducibility and quality of cell cultures in the development of manufacturing processes for cell and gene therapy products.
Advertisement 2
Article content
Article content
Article content
The Analytical Scientist focuses on the people, technology and innovations that make up the science of measurement. The publication issues its annual Innovation Awards to recognize technological advances that are poised to open doors in analytical science.
In the research of new cell and gene therapies (CGT), it is important to evaluate the cell environment and create a suitable environment for cell culture. LiCellMo allows researchers to visualize metabolic changes in cell cultures in real time, providing a complete picture of cell activity for research use in CGT. Instead of requiring researchers to periodically take samples of the culture medium to check cell composition, which can make it difficult to monitor changes in cell conditions over time and risk contamination, LiCellMo provides minute-by-minute measurements of glucose and lactate levels. it’s in the culture. LiCellMo can be easily installed in an existing laboratory CO compatible2 incubator without change in the normal culture environment. It offers researchers a flexible solution to the challenges they face in conventional cell culture methods.
PHC Corporation is a subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global conglomerate of healthcare companies collectively referred to as the PHC Group. Inline monitoring technology4 included in LiCellMo builds on proprietary technology from a blood glucose monitoring sensor developed by another division of PHC Corporation, the In Vitro Diagnostics (IVD) Division.
Chikara Takauo, Director of PHC Corporation and Head of Biomedical Division, said, “We believe that LiCellMo will provide researchers with an opportunity to gain unprecedented new information about cell metabolism, especially in the field of cancer immunology and stem cell research, and improve productivity. the process of new treatment in those fields. This award is a recognition of both LiCellMo’s pioneering role in research and its promise to support the development of future therapies.”
1 theanalyticalscientist.com/techniques-tools/the-analytical-scientist-innovation-awards-2024-10
2 www.phchd.com/global/phc/news/2024/0904
3 A series of biochemical reactions within cultured cells produce the energy needed for cellular function and survival.
4 A technology that allows the continuous measurement of mobile metabolites in the culture medium without the need for samples, which is achieved by maintaining constant immersion in the medium.
Advertisement 3
Article content
About Biomedical Division of PHC Corporation
Founded in 1969, PHC Corporation is the Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, markets, and services solutions in diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry by assisting researchers and healthcare providers in approximately 110 countries and territories through its PHCbi-branded laboratory and equipment and services including CO.2 incubators and freezers at very low temperatures.
www.phchd.com/global/phc
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission to contribute to public health through healthcare solutions that positively impact and improve people’s lives. Its subsidiaries (collectively referred to as the PHC Group) include PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s total sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
View the source version on businesswire.com: https://www.businesswire.com/news/home/20241211103952/en/
Contacts
Contact for media inquiries:
Julia Cottrill
Company PHC Holdings Corporation
Email: [email protected]
Contact product and service:
Marketing Department, Biomedical Division PHC Corporation
Email: [email protected]
#distro
Article content
Source link
